ACTU

Actuate Therapeutics Inc (ACTU) Economic Moat Analysis (2026)

Invetso Score: 2.2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.4 (Weak)

ACTU has no evident filing-backed brand, patent, or regulatory franchise that would let it charge meaningfully better prices than peers, so any customer preference appears weak and non-durable.

The provided metrics show deeply negative ROIC/ROCE, which indicates the company is not converting any intangible advantage into superior returns versus peers.

With no disclosed evidence of proprietary IP, exclusive content, or regulated scarcity, the company looks more replicable than differentiated relative to competitors.

Because there is no clear proof of customer willingness to pay a premium, intangible assets do not appear to support durable margin protection over a 5–10 year horizon.

Switching Costs

Score:

The available information does not show contractual lock-in, workflow embedding, or data migration friction, so customers likely can switch with limited economic penalty versus peers.

Negative profitability suggests the company is not retaining customers through embedded economics that would normally show up in stable margins or returns.

Compared with stronger software or platform peers, ACTU does not show evidence of high renewal dependence or integration depth that would raise switching costs.

Without filing evidence of long-duration contracts or mission-critical usage, switching costs appear low and therefore weak as a moat driver.

Network Effects

Score:

There is no evidence of a user, data, or marketplace flywheel that would make the product more valuable as adoption rises, so network effects are not demonstrated.

The company’s negative ROIC/ROCE is inconsistent with a self-reinforcing ecosystem that would typically improve monetization versus peers.

Unlike peer platforms with visible two-sided liquidity or data advantages, ACTU does not show structural dependence by customers or counterparties.

Absent filing-backed proof of ecosystem scale, network effects should be treated as minimal and not a source of durable advantage.

Cost Advantage

Score:

The reported negative returns indicate ACTU is not operating with a clear unit-cost edge that would translate into superior margins versus peers.

No evidence is provided for proprietary supply, scale purchasing, or process automation that would lower costs structurally relative to competitors.

If a cost advantage existed, it would usually support positive and resilient capital returns, but the current metrics point the opposite way.

Relative to peers with demonstrated scale economics, ACTU appears to lack a durable cost position that can defend pricing over time.

Efficient Scale

Score:

The available data do not indicate that ACTU serves a niche market with limited room for multiple profitable competitors, so efficient-scale protection is not evident.

Negative ROIC/ROCE suggests the company is not benefiting from a protected market structure that would normally support above-peer economics.

Compared with regulated or infrastructure-like peers, ACTU does not show signs of capacity constraints or natural monopoly characteristics.

Without evidence of a small addressable market or high fixed-cost barriers that deter entry, efficient scale appears weak.

Overall Score

Score:

ACTU shows no filing-backed evidence of durable moat drivers, and the negative ROIC/ROCE metrics reinforce that any competitive advantage is not translating into peer-leading economics; relative to stronger peers, the business appears highly replicable and weakly protected across all five moat dimensions.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Actuate Therapeutics Inc. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →